Nomogram to predict rectal toxicity following prostate cancer radiotherapy

被引:29
作者
Delobel, Jean-Bernard [1 ]
Gnep, Khemara [2 ,3 ]
David Ospina, Juan [2 ,4 ]
Beckendorf, Veronique [5 ]
Chira, Ciprian [5 ]
Zhu, Jian [2 ,7 ,8 ]
Bossi, Alberto [6 ]
Messai, Taha [6 ]
Acosta, Oscar [2 ]
Castelli, Joel [2 ,3 ]
de Crevoisier, Renaud [2 ,3 ,8 ]
机构
[1] Ctr Hosp Univ Pontchaillou, Dept Gastroenterol, Rennes, France
[2] Univ Rennes 1, INSERM, U1099, LTSI, Rennes, France
[3] Ctr Eugene Marquis, Rennes, France
[4] Univ Nacl Colombia, Escuela Estadist, Medellin, Colombia
[5] Ctr Alexis Vautrin, Vandoeuvre Les Nancy, France
[6] Inst Gustave Roussy, Villejuif, France
[7] Southeast Univ, Lab Image Sci & Technol, Nanjing, Jiangsu, Peoples R China
[8] CRIBs, Rennes, France
来源
PLOS ONE | 2017年 / 12卷 / 06期
关键词
MODULATED RADIATION-THERAPY; CONVENTIONALLY FRACTIONATED RADIOTHERAPY; DOSE-ESCALATION TRIAL; CONFORMAL RADIOTHERAPY; RANDOMIZED-TRIAL; INCREASED RISK; 68; GY; ASSOCIATION; MULTICENTER; FAILURE;
D O I
10.1371/journal.pone.0179845
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background To identify predictors of acute and late rectal toxicity following prostate cancer radiotherapy (RT), while integrating the potential impact of RT technique, dose escalation, and moderate hypofractionation, thus enabling us to generate a nomogram for individual prediction. Methods In total, 972 patients underwent RT for localized prostate cancer, to a total dose of 70 Gy or 80 Gy, using two different fractionations (2 Gy or 2.5 Gy/day), by means of several RT techniques (3D conformal RT [3DCRT], intensity-modulated RT [IMRT], or image-guided RT [IGRT]). Multivariate analyses were performed to identify predictors of acute and late rectal toxicity. A nomogram was generated based on the logistic regression model used to predict the 3-year rectal toxicity risk, with its accuracy assessed by dividing the cohort into training and validation subgroups. Results Mean follow-up for the entire cohort was 62 months, ranging from 6 to 235. The rate of acute Grade >= 2 rectal toxicity was 22.2%, decreasing when combining IMRT and IGRT, compared to 3DCRT (RR = 0.4, 95% CI: 0.3-0.6, p< 0.01). The 5-year Grade >= 2 risks for rectal bleeding, urgency/tenesmus, diarrhea, and fecal incontinence were 9.9%, 4.5%, 2.8%, and 0.4%, respectively. The 3-year Grade >= 2 risk for overall rectal toxicity increased with total dose (p< 0.01, RR = 1.1, 95% CI: 1.0-1.1) and dose per fraction (2Gy vs. 2.5Gy) (p = 0.03, RR = 3.3, 95% CI: 1.1-10.0), and decreased when combining IMRT and IGRT (RR = 0.50, 95% CI: 0.3-0.8, p< 0.01). Based on these three parameters, a nomogram was generated. Conclusions Dose escalation and moderate hypofractionation increase late rectal toxicity. IMRT combined with IGRT markedly decreases acute and late rectal toxicity. Performing combined IMRT and IGRT can thus be envisaged for dose escalation and moderate hypofractionation. Our nomogram predicts the 3-year rectal toxicity risk by integrating total dose, fraction dose, and RT technique.
引用
收藏
页数:16
相关论文
共 50 条
  • [1] Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial
    Aluwini, Shafak
    Pos, Floris
    Schimmel, Erik
    Krol, Stijn
    van der Toorn, Peter Paul
    de Jager, Hanja
    Alemayehu, Wendimagegn Ghidey
    Heemsbergen, Wilma
    Heijmen, Ben
    Incrocci, Luca
    [J]. LANCET ONCOLOGY, 2016, 17 (04) : 464 - 474
  • [2] [Anonymous], 2009, J EXP CLIN CANC RES
  • [3] Updated Results and Patterns of Failure in a Randomized Hypofractionation Trial for High-risk Prostate Cancer
    Arcangeli, Stefano
    Strigari, Lidia
    Gomellini, Sara
    Saracino, Biancamaria
    Petrongari, Maria Grazia
    Pinnaro, Paola
    Pinzi, Valentina
    Arcangeli, Giorgio
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 84 (05): : 1172 - 1178
  • [4] 70 GY VERSUS 80 GY IN LOCALIZED PROSTATE CANCER: 5-YEAR RESULTS OF GETUG 06 RANDOMIZED TRIAL
    Beckendorf, Veronique
    Guerif, Stephane
    Le Prise, Elisabeth
    Cosset, Jean-Marc
    Bougnoux, Agnes
    Chauvet, Bruno
    Salem, Naji
    Chapet, Olivier
    Bourdain, Sylvain
    Bachaud, Jean-Marc
    Maingon, Philippe
    Hannoun-Levi, Jean-Michel
    Malissard, Luc
    Simon, Jean-Marc
    Pommier, Pascal
    Hay, Men
    Dubray, Bernard
    Lagrange, Jean-Leon
    Luporsi, Elisabeth
    Bey, Pierre
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 80 (04): : 1056 - 1063
  • [5] Association of single nucleotide polymorphisms in SOD2, XRCC1 and XRCC3 with susceptibility for the development of adverse effects resulting from radiotherapy for prostate cancer
    Burri, Ryan J.
    Stock, Richard G.
    Cesaretti, Jamie A.
    Atencio, David P.
    Peters, Sheila
    Peters, Christopher A.
    Fan, Grace
    Stone, Nelson N.
    Ostrer, Harry
    Rosenstein, Barry S.
    [J]. RADIATION RESEARCH, 2008, 170 (01) : 49 - 59
  • [6] Intensity-modulated radiation therapy: Supportive data for prostate cancer
    Cahlon, Oren
    Hunt, Margie
    Zelefsky, Michael J.
    [J]. SEMINARS IN RADIATION ONCOLOGY, 2008, 18 (01) : 48 - 57
  • [7] Contrasting analytical and data-driven frameworks for radiogenomic modeling of normal tissue toxicities in prostate cancer
    Coates, James
    Jeyaseelan, Asha K.
    Ybarra, Norma
    David, Marc
    Faria, Sergio
    Souhami, Luis
    Cury, Fabio
    Duclos, Marie
    El Naga, Issam
    [J]. RADIOTHERAPY AND ONCOLOGY, 2015, 115 (01) : 107 - 113
  • [8] TOXICITY CRITERIA OF THE RADIATION-THERAPY ONCOLOGY GROUP (RTOG) AND THE EUROPEAN-ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER (EORTC)
    COX, JD
    STETZ, J
    PAJAK, TF
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1995, 31 (05): : 1341 - 1346
  • [9] Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer
    D'Amico, AV
    Whittington, R
    Malkowicz, SB
    Schultz, D
    Blank, K
    Broderick, GA
    Tomaszewski, JE
    Renshaw, AA
    Kaplan, I
    Beard, CJ
    Wein, A
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (11): : 969 - 974
  • [10] Association of DNA repair and steroid metabolism gene polymorphisms with clinical late toxicity in patients treated with conformal radiotherapy for prostate cancer
    Damaraju, S
    Murray, D
    Dufour, J
    Carandang, D
    Myrehaug, S
    Fallone, G
    Field, C
    Greiner, R
    Hanson, J
    Cass, CE
    Parliament, M
    [J]. CLINICAL CANCER RESEARCH, 2006, 12 (08) : 2545 - 2554